The Business Research Company’s report on the Induced Pluripotent Stem Cell (iPSC) Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How have key drivers contributed to the rapid growth of the induced pluripotent stem cell (ipsc) market?
An increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of the induced pluripotent stem cell market. Chronic disorders such as heart disease, cancer, stroke, diabetes can be treated with Induced pluripotent stem cell. Induced Pluripotent stem cells are taken from any tissues from a child or an adult and are genetically modified to behave such as embryonic stem cells. According to the report published by Partnership to Fight Chronic Disorder (PFCD), it was found that out of 133 million Americans, 45% of the population had at least one chronic disorder. Moreover, it was estimated that 7 out of 10 deaths in the USA, which is approximately 1.7 million, are due to chronic disorders and these deaths can be controlled by induced pluripotent stem cell treatment. This rise in incidences of chronic diseases is driving the demand for induced pluripotent stem cell treatment market.
Access Your Free Sample of the Global Induced Pluripotent Stem Cell (iPSC) Market Report – Get Insights Now!
Induced Pluripotent Stem Cell Market Report 2025
How has the induced pluripotent stem cell (ipsc) market size evolved, and what are the latest forecasts for its expansion?
The induced pluripotent stem cell (iPSC) market size has grown rapidly in recent years. It will grow from $3.3 billion in 2024 to $3.67 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to increasing healthcare expenditure, a rise in funding, rising awareness of stem cell products’ medicinal potential, use of induced pluripotent stem cell (IPSC) based drug discovery, increasing demand for personalized medicine and cost-effective benefits of IPSC for drug discovery.
The induced pluripotent stem cell (iPSC) market size is expected to see strong growth in the next few years. It will grow to $5.29 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to an increasing prevalence of chronic diseases, growth in genomic projects, development of IPSC-derived disease models, an increasing prevalence of genetic diseases, government initiatives and a rapid increase in technology. Major trends in the forecast period include development of pluripotent stem cells for Parkinson’s disease (PD), strategic collaborations and partnerships, development of induced pluripotent stem cell IPSC-derived nk cells, development of induced pluripotent stem cell (IPSC) for cell therapy, investment in regenerative medicine research and development, development of IPSC expansion medium, development of personalized IPSC and development of pluripotent stem cells for type I diabetes.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
Induced Pluripotent Stem Cell Market Report 2025
Which major companies dominate the induced pluripotent stem cell (ipsc) market?
Major companies operating in the induced pluripotent stem cell (iPSC) market include FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc), Thermo Fisher Scientific, Inc, Takara Bio, Inc, Lonza Group AG, Astellas Pharma Inc, ViaCyte, Inc, Ncardia, REPROCELL USA, Inc, Japan Tissue Engineering Co., Ltd, Merck KGaA, Cynata Therapeutics Limited, Dainippon Sumitomo Pharma, Shenzhen Bioscience, Shanghai Cell Therapy Group, Car-T Bio, JW therapeutics, Fosun Kite Biotechnology, Shanghai UniCar Therapy, Takaria Bio, SEED Biosciences SA, Cellerix, CellGenix, NsGene, TiGenix, Renuron Group, Smart Cells, Genenta Science, Biocad Rf, MSD, Pfizer, Roche, Pharmasyntez, Selvita, Mabion, Pure Biologics, OncoArendi Therapeutics, Proteon Pharmaceuticals, GlaxoSmithKline, Parexel, Bayer, Fate Therapeutics, Athersys, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, Pluristem Therapeutics, Gamida Cell, VistaGen Therapeutics, Caladrius Biosciences, BioCanRx, CellCAN, CCRM, C3i, BioCells Argentina, Stem Cells, Royan Stem Cell Technology Co., Next BioSciences, CryoSave, BioHeart
What trends will shape the future of the independent artists and performing art companies market?
Companies in the Induced Pluripotent stem cell market are looking for opportunities for strategic partnerships and collaborations that will help these companies to enter into new geographies and to expand product portfolios. For example, in January 2022, Bristol Myers Squibb and Century Therapeutics entered into a strategic collaboration to develop IPSC-derived allogenic cell therapies for the treatment of acute myeloid leukemia and multiple myeloma. Furthermore, in May 2022, Evotec and Sernova announced strategic partnership to develop IPSC-based beta cell replacement therapy for treatment for type 1 and type 2 diabetes.
Which region dominates the induced pluripotent stem cell (ipsc) market, and what factors contribute to its leadership?
North America was the largest region in the induced pluripotent stem cell (IPSC) market in 2024. Western Europe was the second largest region in the global induced pluripotent stem cell (IPSC) market share. The regions covered in the induced pluripotent stem cell (IPSC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
Induced Pluripotent Stem Cell Market Report 2025
How is the induced pluripotent stem cell (ipsc) market segmented, and which segment holds the largest share?
The induced pluripotent stem cell (iPSC) market covered in this report is segmented –
1) By Derived Cell Type: Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Other Derived Cell Types
2) By Application: Academic Research, Drug Discovery And Toxicity Studies, Regenerative Medicine, Cell And Gene Therapy
3) By End-User: Hospitals, Research Laboratories
Subsegments:
1) By Hepatocytes: iPSC-Derived Liver Cells For Drug Toxicity Testing, Disease Modeling And Regenerative Therapies
2) By Fibroblasts: iPSC-Derived Skin Cells For Wound Healing And Tissue Repair, Fibroblast-Based Disease Research
3) By Keratinocytes: iPSC-Derived Skin Cells For Dermatological Research, Skin Regeneration Therapies
4) By Amniotic Cells: iPSC-Derived Cells For Prenatal Research, Amniotic Fluid-Based Regenerative Applications
5) By Other Derived Cell Types: Neurons For Neurological Disease Modeling, Cardiomyocytes For Heart Disease Studies, Endothelial Cells For Vascular Research
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
Induced Pluripotent Stem Cell Market Report 2025
What defines the structure and scope of the induced pluripotent stem cell (ipsc) market?
Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as from hepatocytes, fibroblasts, keratinocytes, and neurons. This process involves introducing specific genes that induce the cell to become pluripotent, meaning it can differentiate into any cell type in the body (e.g., heart, brain, liver cells).
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
